期刊文献+

索拉非尼联合5-氟尿嘧啶治疗晚期肝癌的临床研究 被引量:9

下载PDF
导出
摘要 目的观察索拉非尼联合5-氟尿嘧啶治疗晚期肝癌的临床疗效及安全性。方法研究对象入组标准为Child-Pugh分级为A^B级、美国东部肿瘤协作组(ECOG)活动状态(PS)评分为0~1分、无肿瘤治疗史且不适合局部治疗的晚期肝癌患者。具体治疗方案为:索拉非尼400 mg,2次/d,口服,第1~14天;5-氟尿嘧啶200 mg/m2,1次/d泵入,第1~14天;每3周为1个周期。结果根据研究对象入组标准,共计39例患者入组,其中ECOG PS评分0分患者29例,1分患者10例;Child-Pugh A级患者36例,B级患者3例。1例患者达到部分缓解;18例患者达到疾病稳定;入组患者中位随访时间为16.2个月;中位疾病进展生存期为8.0个月(95%CI=5.7~10.4);中位总生存期为13.7个月(95%CI=9.5~17.9)。结论索拉非尼联合5-氟尿嘧啶治疗晚期肝癌具有较好的可行性和安全性,并可有效提高患者疾病控制率,显著延长患者疾病进展生存期和总生存期。
出处 《临床和实验医学杂志》 2013年第19期1573-1574,共2页 Journal of Clinical and Experimental Medicine
  • 相关文献

参考文献12

  • 1Del Gaudio M,Grazi GL,Principe A,et al.Influence of prognostic factors on the outcome of liver transplantation for hepatocellular carcinoma on cirrhosis:a univariate and multivariate analysis[J].Hepatogastroenterology,2004,51(56):510-514.
  • 2Lata J.Chronic liver diseases as liver tumor precursors[J].Dig Dis,2010,28(4-5):596-599.
  • 3Llovet JM,Di Bisceglie AM,Bruix J,et al.Design and endpoints of clinical trials in hepatocellular carcinoma[J].J Natl Cancer Inst,2008,100(10):698-711.
  • 4Llovet JM.Updated treatment approach to hepatocellular carcinoma[J].J Gastroenterol,2005,40(3):225-235.
  • 5Llovet JM,Ricci S,Mazzaferro V,et al.Sorafenib in advanced hepatocellular carcinoma[J].N Engl J Med,2008,359(4):378-390.
  • 6Cheng AL,Kang YK,Chen Z,et al.Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma:aphase III randomised,double-blind,placebo-controlled trial[J].Lancet Oncol,2009,10(1):25-34.
  • 7张志明,黎乐群,刘剑勇,袁卫平,吴飞翔,向邦德,黄山,赵荫农.索拉非尼治疗晚期原发性肝癌的疗效和安全性分析[J].临床肿瘤学杂志,2010,15(4):352-354. 被引量:15
  • 8Joensuu H,De Braud F,Grignagni G,et al.Vatalanib for metastatic gastrointestinal stromal tumour (GIST) resistant to imatinib:final results of a phase IIstudy[J].Br J Cancer,2011,104(11):1686-1690.
  • 9Chang YS,Adnane J,Trail PA,et al.Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models[J].Cancer Chemother Pharmacol,2007,59(5):561-574.
  • 10王宝太,李宗芳.肝癌的药物治疗及进展[J].临床和实验医学杂志,2009,8(3):135-136. 被引量:2

二级参考文献17

  • 1蒋红.饮食与肿瘤[J].实用医技杂志,2007,14(7):885-886. 被引量:16
  • 2叶本法,沈靖,徐耀初.中国原发性肝癌流行病学(兼述24年来启东肝癌流行病学特征及危险因素研究)[J].江苏预防医学,1996,7(1):3-6. 被引量:3
  • 3Tanaka S,Arii S.Molecularly targeted therapy for hepatocellular carcinoma[J].Cancer Sci,2009,100 (1):1-8.
  • 4O'Neil BH,Venook AP.Hepatocellular carcinoma:the role of the North American GI Steering Committee Hepatobiliary Task Force and the advent of effective drug therapy[J].Oncologist,2007,12(12):1425-1432.
  • 5Zhu AX.Development of sorafenib and other molecularly targeted agents in hepatocellular carcinoma[J].Cancer,2008,112(2):250-259.
  • 6Kelley RK,Venook AP.Sorafenib in hepatocellular carcinoma:separating the hype from the hope[J].J Clin Oncol,2008,26(36):5845-5848.
  • 7Gish RG,Baron A.Hepatocellular carcinoma (HCC):current and evolving therapies[J].Idrugs,2008,11(3):198-203.
  • 8Ono T,Yamanoi A,Nazmy El Assal O,et al.Adjuvant chemotherapy after resection of hepatocellular carcinoma causes deterioration of long-term prognosis in cirrhotic patients: metaanalysis of three randomized controlled trials[].Cancer.2001
  • 9Takayama T,Sekine T,Makuuchi M,et al.Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomized trial[].The Lancet.2000
  • 10Kouroumalis E,Skordilis P,Thermos K,et al.Treatment of hepatocellular carcinoma with octreotide: a randomized controlled study[].Gut.1998

共引文献23

同被引文献87

引证文献9

二级引证文献61

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部